Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Operating Margin (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Operating Margin for 6 consecutive years, with 9.0% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin fell 1420.0% year-over-year to 9.0%, compared with a TTM value of 20.04% through Dec 2025, down 980.0%, and an annual FY2025 reading of 20.04%, down 980.0% over the prior year.
  • Operating Margin was 9.0% for Q4 2025 at Cytek Biosciences, up from 17.58% in the prior quarter.
  • Across five years, Operating Margin topped out at 12.53% in Q2 2021 and bottomed at 36.12% in Q1 2025.
  • Average Operating Margin over 5 years is 8.62%, with a median of 7.49% recorded in 2022.
  • The sharpest move saw Operating Margin skyrocketed 1619bps in 2021, then plummeted -2607bps in 2023.
  • Year by year, Operating Margin stood at 3.39% in 2021, then crashed by -95bps to 0.17% in 2022, then tumbled by -235bps to 0.24% in 2023, then skyrocketed by 2308bps to 5.2% in 2024, then tumbled by -273bps to 9.0% in 2025.
  • Business Quant data shows Operating Margin for CTKB at 9.0% in Q4 2025, 17.58% in Q3 2025, and 23.3% in Q2 2025.